Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0MELRN
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
bC2027
|
|||||
| Synonyms |
BC2027
Click to Show/Hide
|
|||||
| Organization |
BioCity Biopharmaceutics (Originator)
|
|||||
| Drug Status |
Phase 1
|
|||||
| Antibody Name |
Anti-GPC3 antibody
|
Antibody Info | ||||
| Antigen Name |
Glypican-3 (GPC3)
|
Antigen Info | ||||
| Payload Name |
TOP1 inhibitor
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
A cleavable linker
|
Linker Info | ||||
| Conjugate Type |
Undisclosed
|
|||||
The indication landscape of This ADC(2027 Update)
The clinical trial pipeline of This ADC(2027 Update)
| Indication | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | New Drug Application | Approved | ||
|---|---|---|---|---|---|---|---|---|---|
| Liver cancer |
1 Trials
|
||||||||
| Lung cancer |
1 Trials
|
||||||||
| Oesophageal cancer |
1 Trials
|
||||||||
| Ovarian cancer |
1 Trials
|
||||||||
| Sarcomas |
1 Trials
|
||||||||
| Unspecific solid tumor |
1 Trials
|